BIOA insider plans sale of 27,000 shares

BIOA filed a Form 144 notice for a planned sale of 27,000 shares of its common stock.

Accepted by SEC EDGAR 01/13/2026 - 04:16 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

BIOA filed a Form 144 notice for a planned sale of 27,000 shares of its common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $531,828.03. The filing notes that 35,855,037 shares of the issuer’s common stock are outstanding. The 27,000 shares were acquired on 01/13/2026 through the cash exercise of an option that was granted on 04/17/2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BIOA shares are planned to be sold under this Form 144?

The Form 144 covers a planned sale of 27,000 shares of BIOA common stock.

What is the aggregate market value of the BIOA shares in this Form 144?

The 27,000 BIOA common shares have an aggregate market value of $531,828.03 as stated in the filing.

On which exchange will the BIOA shares be sold and through which broker?

The shares are to be sold on NASDAQ through Fidelity Brokerage Services LLC.

How and when were the 27,000 BIOA shares acquired?

The 27,000 shares were acquired on 01/13/2026 via cash exercise of an option that was granted on 04/17/2024 by the issuer.

How many BIOA shares are outstanding according to this Form 144?

The filing reports that 35,855,037 shares of BIOA common stock are outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001120478
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BioAge Labs, Inc.
SEC File Number	001-42279
Address of Issuer	5885 HOLLIS STREET SUITE 370 EMERYVILLE CALIFORNIA 94608
Phone	510-806-1445
Name of Person for Whose Account the Securities are To Be Sold	GOLDSTEIN DOV A MD
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	27000	531828.03	35855037	01/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/13/2026	Option Granted - 04/17/2024	Issuer			27000	01/13/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Dov Goldstein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)